echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The anti-COVID-19 monoclonal antibody candidate drug CT-P59:Phase I clinical trials obtained positive results.

    The anti-COVID-19 monoclonal antibody candidate drug CT-P59:Phase I clinical trials obtained positive results.

    • Last Update: 2020-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Celltrion, a pharmaceutical company, recently published the interim results of a Phase I clinical trial of CT-P59 (a drug candidate against COVID-19 monoclonal antibodies), which showed that CT-P59 has good safety, toerability and pharmacodynamics.
    phase I clinical trial was a randomized, double-blind and placebo-controlled trial designed to assess the safety, toerability and pharmacodynamics of CT-P59 in healthy subjects.
    results showed that there were no significant drug-related adverse events (AE) and no adverse events occurred in the maximum to-dosage group. "In addition to these encouraging safety results, we launched commercial production of CT-P59 this month to ensure that if the trials are successful, we can meet the urgent needs of the global fight against virus therapy," said Dr. Sang Jon Lee, Senior Executive Vice President,
    Celltrion.
    Celltrion has launched a global Phase I clinical trial of CT-P59 in patients with mild COVID-19 and plans to conduct further Phase II and PHASE III trials in 12 countries, including South Korea.
    CT-P59 has been identified as a potential treatment for COVID-19.
    in preclinical data, the drug candidate was able to reduce the load of sars-CoV-2 virus by 100 times and reduce inflammation of the lungs.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.